Business Description
Eisai Co Ltd
ISIN : JP3160400002
Share Class Description:
ESALF: Ordinary SharesDescription
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.91 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | 1.54 | |||||
Interest Coverage | 22.36 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.86 | |||||
Beneish M-Score | -2.43 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -34 | |||||
3-Year EBITDA Growth Rate | -33.8 | |||||
3-Year EPS without NRI Growth Rate | -36.8 | |||||
3-Year FCF Growth Rate | -39.8 | |||||
3-Year Book Growth Rate | 7.6 | |||||
Future 3-5Y Total Revenue Growth Rate | 5.72 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 80.88 | |||||
9-Day RSI | 68.13 | |||||
14-Day RSI | 61.42 | |||||
6-1 Month Momentum % | -14.77 | |||||
12-1 Month Momentum % | -36.02 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.37 | |||||
Quick Ratio | 1.8 | |||||
Cash Ratio | 1 | |||||
Days Inventory | 370.43 | |||||
Days Sales Outstanding | 95.64 | |||||
Days Payable | 158.69 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.4 | |||||
Dividend Payout Ratio | 0.99 | |||||
Forward Dividend Yield % | 2.37 | |||||
5-Year Yield-on-Cost % | 2.52 | |||||
Shareholder Yield % | 0.72 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 79.06 | |||||
Operating Margin % | 7.2 | |||||
Net Margin % | 5.72 | |||||
FCF Margin % | 4.15 | |||||
ROE % | 5.05 | |||||
ROA % | 3.21 | |||||
ROIC % | 3.92 | |||||
ROC (Joel Greenblatt) % | 22.46 | |||||
ROCE % | 6.27 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 41.76 | |||||
PE Ratio without NRI | 41.76 | |||||
Shiller PE Ratio | 8.79 | |||||
Price-to-Owner-Earnings | 75.29 | |||||
PS Ratio | 2.55 | |||||
PB Ratio | 2.16 | |||||
Price-to-Tangible-Book | 3.42 | |||||
Price-to-Free-Cash-Flow | 60.65 | |||||
Price-to-Operating-Cash-Flow | 33.76 | |||||
EV-to-EBIT | 27.15 | |||||
EV-to-Forward-EBIT | 28.16 | |||||
EV-to-EBITDA | 16.83 | |||||
EV-to-Forward-EBITDA | 17.72 | |||||
EV-to-Revenue | 2.35 | |||||
EV-to-Forward-Revenue | 2.7 | |||||
EV-to-FCF | 55.93 | |||||
Price-to-Projected-FCF | 1.55 | |||||
Price-to-Median-PS-Value | 2.8 | |||||
Price-to-Graham-Number | 2.52 | |||||
Price-to-Net-Current-Asset-Value | 9.24 | |||||
Earnings Yield (Greenblatt) % | 3.68 | |||||
FCF Yield % | 1.65 | |||||
Forward Rate of Return (Yacktman) % | -31.36 |